SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

~~June~~July 1517, 2017

Commission File Number: ~~001~~000-~~34559~~50867

Syneron Medical Ltd.

(Translation of registrant’'s name into English)

Industrial Zone, Yokneam Illit 20692, P.O.B. 550, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F S Form 40-F £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes £ No S

If “"Yes”" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ________

Attached hereto and incorporated herein by reference is a press release of the Company, dated ~~June~~July 1517, 2017, entitled “"Syneron Candela ~~Announces~~Completes ~~Shareholder~~Previously ~~Approval~~Announced ofTransaction ~~Proposed~~with ~~Acquisition by~~ Funds Advised by Apax Partners and Becomes a Private Company.”"

This Form 6-K is incorporated by reference into the Company’'s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on November 16, 2004 (Registration No. 333-120559), on January 8, 2010 (Registration No. 333-164250), on January 15, 2010 (Registration No. 333-164351), on December 9, 2013 (Registration No. 333-192729) and on September 8, 2016 (Registration No. 333-213539).

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SYNERON MEDICAL LTD. By: /s/ ~~Hugo~~Sarit ~~Goldman~~Soccary Name: ~~Hugo~~Sarit ~~Goldman~~Soccary Title: ~~Chief~~General ~~Financial~~Manager ~~Officer~~of Syneron Medical Site in Israel

Date: ~~June~~July 1517, 2017

2Syneron Candela Completes Previously Announced Transaction with Funds

~~Syneron~~Advised ~~Candela~~by ~~Announces~~Apax ~~Shareholder~~Partners ~~Approval~~and ofBecomes ~~Proposed~~a ~~Acquisition~~Private by Company

~~Funds~~Announces ~~Advised~~new byexecutive ~~Apax~~leadership ~~Partners~~team headquartered in the U.S.

IRVINE, Calif., ~~June~~July 1517, 2017 – Syneron Medical Ltd. (NASDAQ: ELOS), ~~today~~a ~~announced~~leading ~~that~~global ~~its~~non-surgical ~~shareholders~~aesthetic ~~have~~device ~~approved~~company, today announced the ~~previously~~successful ~~announced~~completion ~~definitive~~of ~~agreement~~its ~~under~~acquisition ~~which~~by an affiliate of funds advised by Apax Partners ~~will acquire all of the outstanding shares of Syneron Candela~~ for $11.00 per share in cash in a transaction valued at approximately $~~397~~400 million ~~(the “Merger Agreement”)~~.

~~93.~~The transaction was announced on April 3%, 2017 and received approval from Syneron Candela's shareholders on June 15, 2017. As a result of the transaction, Syneron Candela is now a privately held company. Syneron Candela's ordinary shares ~~voting~~will atcease ~~the~~to ~~special~~trade ~~shareholder~~on ~~meeting~~The ~~were~~Nasdaq ~~voted~~Stock inMarket ~~favor~~before the opening of the ~~Merger~~market ~~Agreement~~today and will be delisted.

~~The~~In ~~acquisition~~conjunction iswith ~~expected~~the closing of the transaction, Geoffrey Crouse has been appointed Chief Executive Officer and a member of the Board of Directors of Syneron Candela. Mr. Crouse has successfully led businesses in the life sciences sector spanning capital equipment, diagnostics and tools. Prior to bejoining ~~completed~~Syneron Candela, he served as Chief Executive Officer of Cord Blood Registry from 2012 to 2015, when the company was sold to AMAG Pharmaceuticals. Prior, he served as Chief Operating Officer of Immucor, a publicly traded company in ~~mid~~the in-~~July~~vitro diagnostics marketplace, ~~subject~~and toled Health Economics and Reimbursement Outcomes for Roche Diagnostics. Mr. Crouse currently serves as a member of the ~~satisfaction~~Board of Directors at Invitae Corporation (NYSE: NVTA) and Prelude Fertility. Mr. Crouse holds a B.A. in English from Boston College, an MBA and a Masters of Public Health, from the ~~remaining~~University ~~closing~~of ~~conditions~~California, Berkeley.

Mr. Crouse said, "I am excited to join Syneron Candela. I have been very impressed with the potential of the Syneron Candela business and the passion of the Company's talented employees. I see a real opportunity to re-ignite growth in the business through a relentless focus on our customers' success and by building on the strength of Syneron Candela's brands, the technology behind its products, and the high quality of the Company's engineering and product development organization."

Also joining Syneron Candela's senior executive team are Mike Johnson as Chief Financial Officer, Mary Trout as President, Americas, and Todd Van Horn as Chief Business Officer. Mr. Crouse, Mr. Johnson, Mrs. Trout, and Mr. Van Horn served together as members of Cord Blood Registry's executive team, and collectively bring over 60 years of experience in life science and medical device businesses. The Company's newly appointed executives will be headquartered in the United States in the San Francisco Bay Area.

Barclays acted as exclusive financial advisor to Syneron Candela. Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co. and Morrison & Foerster LLP served as legal advisors. J.P. Morgan served as financial advisor to Apax Partners and Simpson Thacher & Bartlett LLP and Meitar Liquornik Geva Leshem Tal served as legal advisors.

About Syneron Candela

Syneron Candela is a leading global non-surgical aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, women's intimate health, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company has a wide portfolio of trusted, leading products including UltraShape Power, VelaShape, CO₂RE, CO₂RE Intima, GentleLase, VBeam Perfecta, PicoWay, Profound and elōs Plus.

Founded in 2000 ~~and headquartered in Israel~~, Syneron Candela has R&D and manufacturing operations in Israel and the U.S. The company markets, services and supports its products in nearly 100 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include statements regarding the expected timing of the proposed acquisition. Such "forward looking statements" involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. Achievement of these results by the Company may be affected by many factors, including, but not limited to, risks and uncertainties regarding the ability to close the proposed transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties' ability to satisfy certain closing conditions; the risk that the benefits of the potential transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; the risk that the Company's business may not perform as expected; as well as general economic conditions. Additional information regarding these and other factors is contained in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F. The statements made by the Company are based upon management's current expectations and the Company undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this release except as required by law.

For additional information, please visit http://www.syneron-candela.com.

3 Media Contact

Media and Investor Contacts

Heidi Donato, Cohn & Wolfe (media)

E: Heidi.Donato@cohnwolfe.com

M: +1-516-359-1146

P: +1-516-221-0614

Hugo Goldman, Chief Financial Officer (investors)

Syneron Candela

E: hugo.goldman@syneron-candela.com

P: +972-73-2442200

Zack Kubow (investors)

The Ruth Group

E: zkubow@theruthgroup.com

P: 646-536-7020

Filing Compare · Syneron Medical Ltd.